Indegene Q1 FY27 Results (NSE: INDGN)
Signal: Margin pressure
The read
Revenue surge 40% YoY but PAT flat as other expenses (+85% YoY) and depreciation (+104% YoY) absorb growth; EBITDA margin drops ~420bps YoY to ~19% – after four quarters of margin compression, QoQ margin recovers from 17.4% (Q4FY26, ex-exceptional) to 19.1%, providing a tentative inflection but still below year-ago level.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹1,063.1 Cr | 39.8% | 5.95% |
| EBIT | ₹203.2 Cr | 14.5% | |
| Net profit | ₹116.2 Cr | -0.2% | |
| EPS | ₹4.84 | -0.4% | |
| EBIT margin | 19.1% |
P&L walk
Revenue surged 39.8% YoY driven by Enterprise Commercial Solutions (+44% YoY), but other expenses (+85% YoY) and depreciation (+104% YoY) eroded margins, leaving PAT flat.
Segments
Enterprise Commercial Solutions (70% of revenue) drove growth at +44% YoY, while Enterprise Medical Solutions grew +28% YoY; the 'Others' segment (consulting/clinical) widened its loss to ₹115mn from ₹50mn, dragging group results.
Key positives
- Revenue grew 39.8% YoY, fastest in recent quarters, driven by Enterprise Commercial Solutions (+44% YoY).
- Standalone PAT up 32.8% YoY, indicating better profitability at parent level.
- Employee cost ratio improved 130bps YoY to 62.0% of revenue.
- No exceptional charges in current quarter; prior quarter had ₹203mn litigation provision.
- Segment profit from Medical and Commercial grew 24% and 9% YoY respectively.
Key concerns
- Consolidated PAT flat YoY despite 40% revenue growth due to steep rise in other expenses (+85% YoY) and depreciation (+104% YoY).
- EBITDA margin contracted ~420bps YoY to 19.1%.
- Other expenses as a % of revenue surged 530bps YoY to 21.6%.
- 'Others' segment loss doubled to ₹115mn, indicating weakness in consultancy/clinical business.
- Depreciation doubled YoY, reflecting aggressive acquisition-led asset base growth without commensurate profit improvement.
Research and educational content only. Not investment advice.